Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phil Skolnick

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The International Journal of Neuropsychopharmacology|April 1, 2014
Therapeutic doses of buspirone block D3 receptors in the living primate brainSung Won Kim, Joanna S Fowler, Phil Skolnick, et al.
Alcoholism, Clinical and Experimental Research|December 14, 2011
Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) ratsAndrew R S T Yang, Heon S Yi, Kaitlin T Warnock, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2006
The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptorsPiotr Popik, Emmanuel Kostakis, Martyna Krawczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2007
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic painAnthony S Basile, Aaron Janowsky, Krystyna Golembiowska, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 20, 2007
The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesityJoseph P Tizzano, D Sloan Stribling, Diego Perez-Tilve, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2003
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's diseaseTracey K Murray, Katherine Whalley, Christine S Robinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 12, 2003
The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidumHarry L June, Katrina L Foster, Peter F McKay, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Countermeasures for Preventing and Treating Opioid OverdoseCharles P France, Gerard P Ahern, Saadyah Averick, et al.
Drug and Alcohol Dependence|December 15, 2015
Measures of outcome for stimulant trials: ACTTION recommendations and research agendaBrian D Kiluk, Kathleen M Carroll, Amy Duhig, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The International Journal of Neuropsychopharmacology|April 1, 2014
Therapeutic doses of buspirone block D3 receptors in the living primate brainSung Won Kim, Joanna S Fowler, Phil Skolnick, et al.
Alcoholism, Clinical and Experimental Research|December 14, 2011
Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) ratsAndrew R S T Yang, Heon S Yi, Kaitlin T Warnock, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2006
The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptorsPiotr Popik, Emmanuel Kostakis, Martyna Krawczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2007
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic painAnthony S Basile, Aaron Janowsky, Krystyna Golembiowska, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 20, 2007
The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesityJoseph P Tizzano, D Sloan Stribling, Diego Perez-Tilve, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2003
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's diseaseTracey K Murray, Katherine Whalley, Christine S Robinson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 12, 2003
The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidumHarry L June, Katrina L Foster, Peter F McKay, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Countermeasures for Preventing and Treating Opioid OverdoseCharles P France, Gerard P Ahern, Saadyah Averick, et al.
Drug and Alcohol Dependence|December 15, 2015
Measures of outcome for stimulant trials: ACTTION recommendations and research agendaBrian D Kiluk, Kathleen M Carroll, Amy Duhig, et al.
Pageof 6